Molecular Mechanisms of Combination Adjuvants (MMCA) (R01 Clinical Trial Not Allowed) | RFA AI 25 006

FAQs: Molecular Mechanisms of Combination Adjuvants (MMCA) (RFA AI 25 006)

What is the MMCA funding opportunity?

The Molecular Mechanisms of Combination Adjuvants (MMCA) opportunity (RFA AI 25 006) is a National Institutes of Health (NIH) discretionary grant program using the R01 research project mechanism. It supports basic and translationally oriented mechanistic research on how two or more vaccine adjuvants function together as a combination.

What is the main scientific focus of this NOFO?

The focus is on explaining the molecular and cellular mechanisms that emerge when multiple immune-modulating adjuvants are combined. The goal is not just to show improved immune responses, but to identify why and how the combination produces particular outcomes, including synergistic, additive, or antagonistic interactions.

Are clinical trials allowed under this opportunity?

No. This opportunity explicitly does not allow clinical trials.

What kind of research is considered responsive?

Responsive projects are expected to investigate a clearly defined combination of at least two established immune-modulating adjuvants and include experiments that dissect how the combination changes innate and adaptive immune programming compared with each adjuvant alone. Approaches may include preclinical models, ex vivo human systems, in vitro platforms, and/or computational and systems immunology methods, as long as they are justified for mechanistic clarity.

Is the program meant to fund trial-and-error mixing of adjuvants?

No. The program is designed to move beyond trial-and-error mixing by generating mechanistic insights that make immune outcomes more predictable and support rational vaccine design.

Does the NOFO require a specific number of adjuvants in the combination?

Yes. The emphasis is on combinations of two or more vaccine adjuvants (i.e., at least two components).

Do the adjuvants in the proposed combination need prior evidence of activity?

Yes. Every adjuvant included in a proposed combination must already have demonstrated immune-modulating activity. The opportunity is not intended for testing entirely unproven adjuvant candidates from scratch.

What is meant by "mechanistic" research in this context?

Mechanistic research here means studies that can identify and explain underlying processes and pathways responsible for the combination effect. Examples described include work on pathways, receptors, signaling networks, innate sensing events, antigen-presenting cell programming, tissue microenvironments, or systems-level signatures that explain why certain combinations drive specific immune phenotypes.

What kinds of interaction effects are of interest?

The NOFO highlights interest in synergistic, additive, and antagonistic interactions that may occur when two or more immune modulators are combined.

What immune outcomes is the program trying to make more predictable?

The longer-term goal is to improve predictability of immune profiles elicited by combinations. Examples mentioned include antibody magnitude and quality, T cell polarization, innate signatures, durability, mucosal features, and breadth.

Why does the NOFO emphasize "emergent biology" from combinations?

The opportunity is based on the idea that combination adjuvants can create biological effects that are not seen with single components. The NOFO aims to fund studies that map and explain those emergent effects in ways that support prediction and design.

What is the funding mechanism used for MMCA?

The opportunity uses the NIH R01 research project mechanism.

Does the summary specify an award ceiling or number of awards?

No. The summary information provided does not specify an award ceiling or the expected number of awards.

What does the R01 mechanism generally imply about support?

While the NOFO summary does not provide specific caps, an NIH R01 generally implies substantial multi-year support for a defined research plan, subject to NIH policies and the budget and project period requested and justified by the applicant.

What is the CFDA number and funding activity area for this opportunity?

This opportunity is listed under CFDA 93.855 and is categorized in the Health funding activity area.

What are the key dates listed in the summary?

The NOFO was created on 2025-01-13, and the original application closing date provided is 2025-06-10.

Who is eligible to apply?

Eligibility is broad. Eligible applicants include various government entities (state, county, city or township, and special district governments), independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, Native American tribal governments (federally recognized), tribal organizations that are not federally recognized tribal governments, public housing authorities and Indian housing authorities, nonprofits with and without 501(c)(3) status (when not part of an institution of higher education), for-profit organizations other than small businesses, and small businesses.

Are specialized institution types and community-based organizations eligible?

Yes. The NOFO also highlights eligibility for Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; eligible federal agencies; regional organizations; U.S. territories or possessions; and non-domestic (non-U.S.) entities (foreign organizations).

Are non-U.S. (foreign) organizations eligible to apply?

Yes. Non-domestic (non-U.S.) entities (foreign organizations) are included in the eligibility language.

What types of study systems are appropriate given that clinical trials are not allowed?

Because clinical trials are not allowed, the work would be positioned in preclinical models, ex vivo human systems, in vitro platforms, and/or computational and systems immunology approaches, depending on what is justified for mechanistic clarity.

What is the practical end goal of the research supported by MMCA?

The practical long-term goal is to improve rational vaccine design by producing mechanistic rules, models, or signatures that help anticipate immune outcomes from combination adjuvants, making vaccine optimization more principled and predictable.